Royal Jelly Components Encapsulation in a Controlled Release System-Skin Functionality, and Biochemical Activity for Skin Applications.
10-hydroxy-2-decenoic acid (10-HDA)
controlled release
liposome
polyphenols
royal jelly
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
22 Jul 2022
22 Jul 2022
Historique:
received:
10
06
2022
revised:
15
07
2022
accepted:
19
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Royal jelly is a yellowish-white substance with a gel texture that is secreted from the hypopharyngeal and mandibular glands of young worker bees. It consists mainly of water (50-56%), proteins (18%), carbohydrates (15%), lipids (3-6%), minerals (1.5%), and vitamins, and has many beneficial properties such as antimicrobial, anti-inflammatory, anticancer, antioxidant, antidiabetic, immunomodulatory, and anti-aging. Royal jelly has been used since ancient times in traditional medicine, cosmetics and as a functional food due to its high nutritional value. The main bioactive substances are royalactin, and 10-hydroxy-2-decenoic acid (10-HDA). Other important bioactive molecules with antioxidant and photoprotective skin activity are polyphenols. However, they present difficulties in extraction and in use as they are unstable physicochemically, and a higher temperature causes color change and component degradation. In the present study, a new encapsulation and delivery system consisting of liposomes and cyclodextrins incorporating royal jelly has been developed. The new delivery system aims to the elimination of the stability disadvantages of royal jelly's sensitive component 10-HDA, but also to the controlled release of its ingredients and, more particularly, 10-HDA, for an enhanced bioactivity in cosmeceutical applications.
Identifiants
pubmed: 35893731
pii: ph15080907
doi: 10.3390/ph15080907
pmc: PMC9332036
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Invest Dermatol. 2016 Apr;136(4):738-740
pubmed: 27012558
Jpn J Pharmacol. 1990 Jul;53(3):331-7
pubmed: 2391765
Microbiol Res. 2016 Nov;192:130-141
pubmed: 27664731
Int J Pharm. 2005 Sep 30;302(1-2):29-38
pubmed: 16099117
Nature. 2015 Oct 8;526(7572):S4-5
pubmed: 26444373
ACS Omega. 2022 Jan 14;7(4):3731-3737
pubmed: 35128281
Drug Discov Ther. 2019;13(5):268-273
pubmed: 31723098
Life (Basel). 2022 Jan 10;12(1):
pubmed: 35054487
ACS Omega. 2019 Jun 21;4(6):10866-10876
pubmed: 31460184
Plants (Basel). 2021 Feb 23;10(2):
pubmed: 33672417
J Cell Biol. 1997 Feb 10;136(3):729-43
pubmed: 9024701
Sci Rep. 2018 Jan 9;8(1):162
pubmed: 29317682
Front Zool. 2013 Nov 27;10(1):72
pubmed: 24279675
Molecules. 2018 May 11;23(5):
pubmed: 29751694
J Invest Dermatol. 2016 Apr;136(4):847-858
pubmed: 26802933
Nutrients. 2021 Feb 07;13(2):
pubmed: 33562330
Int J Mol Sci. 2020 Jan 08;21(2):
pubmed: 31936187
Trop Biomed. 2008 Dec;25(3):243-51
pubmed: 19287364
Toxicol Pathol. 2008 Jan;36(1):30-42
pubmed: 18337219
J Zhejiang Univ Sci B. 2018 Dec.;19(12):960-972
pubmed: 30507079
J Proteome Res. 2008 Aug;7(8):3339-53
pubmed: 18597515
Eur J Pharm Biopharm. 2009 Jun;72(2):317-23
pubmed: 18775778
PLoS One. 2015 Mar 18;10(3):e0120091
pubmed: 25785582
Colloids Surf B Biointerfaces. 2010 Nov 1;81(1):11-9
pubmed: 20638250
Biotechnol Adv. 1994;12(2):325-39
pubmed: 14545896
Oncotarget. 2018 Jan 3;9(4):5480-5491
pubmed: 29435195
Sci Rep. 2021 Dec 15;11(1):24056
pubmed: 34911993
J Transl Med. 2019 Jul 31;17(1):247
pubmed: 31366356
Adv Exp Med Biol. 2015;822:195-8
pubmed: 25416990
EMBO Rep. 2011 Mar;12(3):238-43
pubmed: 21331099
Molecules. 2018 Dec 07;23(12):
pubmed: 30544571
Int J Mol Sci. 2021 Nov 30;22(23):
pubmed: 34884772
Int J Mol Sci. 2019 Sep 20;20(19):
pubmed: 31547049
J Ethnopharmacol. 2010 Mar 24;128(2):314-21
pubmed: 20138211
J Asthma Allergy. 2021 Dec 22;14:1555-1557
pubmed: 35221696
Front Bioeng Biotechnol. 2021 Sep 09;9:705886
pubmed: 34568298
Int J Mol Sci. 2020 Jun 21;21(12):
pubmed: 32575820
Molecules. 2020 Jan 28;25(3):
pubmed: 32012913
Cancer Res. 2008 May 1;68(9):3124-32
pubmed: 18451137
Sci Rep. 2017 Aug 4;7(1):7340
pubmed: 28779102
Pharm Dev Technol. 2015 Nov;20(7):775-781
pubmed: 24856960
J Med Food. 2011 Sep;14(9):899-906
pubmed: 21812645
Respirology. 2018 Jan;23(1):68-75
pubmed: 28834088
J Food Biochem. 2021 Feb;45(2):e13619
pubmed: 33491244
PLoS One. 2011;6(8):e23527
pubmed: 21858156
Molecules. 2014 Jun 11;19(6):7798-816
pubmed: 24962387
Mol Biol Cell. 2017 Feb 15;28(4):524-534
pubmed: 27974639
Nanomaterials (Basel). 2018 Oct 18;8(10):
pubmed: 30340318
Exp Gerontol. 2014 Dec;60:129-35
pubmed: 25456847
Int Immunopharmacol. 2007 Sep;7(9):1211-20
pubmed: 17630200
J Diet Suppl. 2018 Sep 3;15(5):757-775
pubmed: 29028361
J Chromatogr A. 2020 Apr 12;1616:460783
pubmed: 31952813
Eur J Dermatol. 2018 Aug 1;28(4):563-564
pubmed: 30396869
Neurosci Lett. 2003 Mar 13;339(1):62-6
pubmed: 12618301